FibroBiologics, Inc.

FibroBiologics, Inc. is a clinical-stage biotechnology company that develops and commercializes fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company's platform utilizes human dermal fibroblasts to create biological therapies across clinical target areas such as wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications, including thymic involution reversal. Its primary therapeutic product candidates include CYWC628 for wound care, CYPS317 for psoriasis, CYMS101 for multiple sclerosis, and CybroCell for degenerative disc disease, targeting chronic patient populations such as those with diabetic foot ulcers.

The company operates its principal executive offices in Houston, Texas, leasing office and temporary laboratory facilities. Its clinical and research programs focus on testing allogeneic fibroblast cell therapies and spheroids, utilizing preclinical mouse models and partnering with clinical research organizations to conduct studies in the United States.

Summary of the business section of FibroBiologics's latest annual report, written by StockData.

“As of December 31, 2025, we had 15 full-time employees, including seven employees with medical or doctoral degrees and nine employees directly engaged in research and development, with the rest providing administrative, business and operations support.”